Sun BioPharma, Inc. (NASDAQ:SNBP) was founded in 2011 and is headquartered in Waconia, Minnesota. It has 4 full-time employees. It is a clinical-stage biopharmaceutical company dedicated to the development of treatments for unmet medical needs. .
Sun BioPharma, Inc. (SNBP):
Sun BioPharma, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of disruptive therapies to meet urgent medical needs. The company’s current focus is on pancreatic diseases, including pancreatitis and pancreatic cancer.
Sun BioPharma’s initial product candidate is SBP-101, a polyamine metabolism inhibitor in clinical development for the treatment of patients with metastatic pancreatic ductal adenocarcinoma, which is in phase Ia/Ib clinical trials.
Sun BioPharma has established scientific research with Cedars Sinai Medical Center, a pancreatic disease expert in Los Angeles, and the University of Miami, University of Florida, Austin Health Cancer Trials Centre in Melbourne, Australia, Ashford Cancer Centre, Australia, and Blacktown Cancer and Haematology Centre in Sydney, Australia. Cooperation.